Johnson & Johnson (JNJ)

May 11, 2025, 7:30 AM EDT - 13 hours ago

Fortress Dividends: 2 Of The Best All-Weather Income Stocks Built To Last

PEP

May 9, 2025, 6:25 PM EDT - 2 days ago

Final Trade: SLV, JNJ, HYG, GOOGL

GOOG GOOGL SLV HYG

May 9, 2025, 4:51 PM EDT - 2 days ago

Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.

NVO NVS SNY

May 9, 2025, 8:14 AM EDT - 2 days ago

J&J's skin disease drug meets main goal in late-stage study

May 9, 2025, 8:05 AM EDT - 2 days ago

Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis

May 8, 2025, 7:23 PM EDT - 3 days ago

Pressure is still on the pharma sector, says Mizuho's Jared Holz

ABBV AMGN BMY GILD LLY MRK NVO

May 8, 2025, 12:07 PM EDT - 3 days ago

Jury Orders Johnson & Johnson to Pay $3 Million in Mesothelioma Death of New Orleans Woman

May 8, 2025, 8:12 AM EDT - 3 days ago

Johnson & Johnson expands efforts to champion the nursing workforce globally

May 8, 2025, 12:45 AM EDT - 3 days ago

Dividend Hikes Offer Optimism Amid Tariff Turmoil

HD LOW M NOBL NVDA PG ROST

May 6, 2025, 11:25 AM EDT - 5 days ago

3 Stable Stocks to Buy When the Price is Right

MSFT

May 5, 2025, 4:56 PM EDT - 6 days ago

Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms

ABBV LLY PFE

May 5, 2025, 8:05 AM EDT - 6 days ago

TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

May 5, 2025, 8:05 AM EDT - 6 days ago

TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years

May 3, 2025, 9:46 AM EDT - 8 days ago

Dogs Of The Dow Chase May's 'Safer' Buy

AMGN AMZN BA CRM CSCO CVX DIS

May 2, 2025, 1:46 PM EDT - 9 days ago

Calls of the Day: AutoZone, Roblox, Eli Lilly, Johnson & Johnson and Quanta Services

AZO LLY PWR RBLX

May 2, 2025, 12:17 AM EDT - 9 days ago

J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports

Apr 30, 2025, 4:12 PM EDT - 11 days ago

Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom

ABBV ABT DXCM GSK LLY MRK NVS

Apr 30, 2025, 1:42 PM EDT - 11 days ago

FDA Approves Johnson & Johnson's IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families

Apr 30, 2025, 8:41 AM EDT - 11 days ago

US FDA approves J&J's immune disorder drug

Apr 30, 2025, 8:29 AM EDT - 11 days ago

Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)

Apr 29, 2025, 8:07 PM EDT - 12 days ago

Best Dividend Aristocrats For May 2025

ABBV ABT ADM ADP AFL ALB AMCR

Apr 28, 2025, 7:16 PM EDT - 13 days ago

Trump to tout US investments from Nvidia, J&J, Hyundai, Toyota

NVDA TM

Apr 28, 2025, 6:00 PM EDT - 13 days ago

My 10 Must-Own Dividend Stocks For Your Retirement Portfolio (One Yields 9.65%)

AAPL ARCC BLK CVX MSFT O PEP

Apr 28, 2025, 4:22 PM EDT - 13 days ago

Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference

Apr 26, 2025, 2:00 PM EDT - 15 days ago

Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

Apr 26, 2025, 1:50 PM EDT - 15 days ago

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer

Apr 26, 2025, 1:50 PM EDT - 15 days ago

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer

Apr 25, 2025, 6:06 PM EDT - 16 days ago

We're in a pharma stock pickers market, says Kessef's Len Yaffe

ABBV BMY GILD LLY MRK PFE REGN

Apr 25, 2025, 3:00 AM EDT - 16 days ago

TREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease

Apr 24, 2025, 7:46 AM EDT - 17 days ago

Johnson & Johnson Just Proved The Bears Wrong Again

Apr 23, 2025, 9:58 AM EDT - 18 days ago

2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market

ABM ABT ADM AWR BDX BKH CWT

Apr 22, 2025, 7:30 AM EDT - 19 days ago

Two Stocks To Consider During Market Unrest To Provide Income Stability

BUD KVUE MO PM XLF XLK XLP

Apr 21, 2025, 9:36 AM EDT - 20 days ago

Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA

Apr 21, 2025, 9:00 AM EDT - 20 days ago

LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed

ABBV AMGN AZN BMY GSK LLY MRK

Apr 18, 2025, 10:15 AM EDT - 23 days ago

Johnson & Johnson: 15% of AI Use Cases Deliver 80% of Value

Apr 18, 2025, 7:00 AM EDT - 23 days ago

Johnson & Johnson Pivots Its AI Strategy

Apr 17, 2025, 8:05 AM EDT - 24 days ago

Why Most Dividend Retirement Strategies Fail: How To Retire With Dividends

AEM BIP BIPC BIZD DIA EPD GLD

Apr 16, 2025, 4:28 PM EDT - 25 days ago

Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

Apr 16, 2025, 12:51 PM EDT - 25 days ago

Healthy Returns: What drugmakers are saying about Trump's looming pharmaceutical tariffs

DXCM LLY

Apr 15, 2025, 3:00 PM EDT - 26 days ago

Two New Dividend Picks To Help You Navigate Tariffs And Uncertainty -- One Yields 7%+

AAPL ARE SCHD SCHO UL

Apr 15, 2025, 1:03 PM EDT - 26 days ago

Johnson & Johnson tops Wall Street expectations in Q1

Apr 15, 2025, 12:42 PM EDT - 26 days ago

Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript

Apr 15, 2025, 11:06 AM EDT - 26 days ago

J&J Expects Tariffs to Cost Company $400 Million

Apr 15, 2025, 10:53 AM EDT - 26 days ago

Johnson & Johnson beats on top and bottom lines

Apr 15, 2025, 10:43 AM EDT - 26 days ago

Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves

Apr 15, 2025, 10:30 AM EDT - 26 days ago

JNJ Raises Guidance Despite Tariffs, ACI Guidance Slump, GM Downgrades

GM ACI

Apr 15, 2025, 8:11 AM EDT - 26 days ago

Johnson & Johnson raised its sales outlook, even with tariff costs included

Apr 15, 2025, 7:28 AM EDT - 26 days ago

Johnson & Johnson CFO on earnings: Guidance has 'a lot more than meets the eye'

Apr 15, 2025, 7:06 AM EDT - 26 days ago

Johnson & Johnson Tops Q1 Estimates, Lifts Full-Year Sales Outlook

Apr 15, 2025, 6:53 AM EDT - 26 days ago

J&J Increases Outlook After Beating 1Q Expectations